• Mi Re-Unir
    Búsqueda Avanzada
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Ver ítem 
    •   Inicio
    • RESULTADOS DE INVESTIGACIÓN
    • Artículos Científicos WOS y SCOPUS
    • Ver ítem
    •   Inicio
    • RESULTADOS DE INVESTIGACIÓN
    • Artículos Científicos WOS y SCOPUS
    • Ver ítem

    COVID-19 Comes 40 Years After AIDS - Any Lesson?

    Autor: 
    Soriano, Vicente (1)
    ;
    Barreiro, Pablo
    ;
    Ramos, José M.
    ;
    Eirós, José M.
    ;
    Mendoza, Carmen de
    Fecha: 
    06/2020
    Palabra clave: 
    SARS-CoV-2; HIV. COVID-19; antiviral treatment; coronavirus; vaccine; Spain; Scopus
    Tipo de Ítem: 
    Articulo Revista Indexada
    URI: 
    https://reunir.unir.net/handle/123456789/10262
    DOI: 
    https://doi.org/10.24875/AIDSRev.M20000030
    Dirección web: 
    http://www.aidsreviews.com/resumen.php?id=1534&indice=2020222&u=unp
    Open Access
    Resumen:
    The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being “with” rather than “by” SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of corticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic.
    Mostrar el registro completo del ítem
    Este ítem aparece en la(s) siguiente(s) colección(es)
    • Artículos Científicos WOS y SCOPUS

    Estadísticas de uso

    Año
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    Vistas
    0
    0
    0
    0
    0
    0
    0
    0
    53
    36
    18
    Descargas
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0

    Ítems relacionados

    Mostrando ítems relacionados por Título, autor o materia.

    • Hospital admissions in individuals with HTLV-1 infection in Spain 

      Ramos, José M.; Mendoza, Carmen de; Aguilera, Antonio; Barreiro, Pablo; Benito, Rafael; Eirós, José M.; Soriano, Vicente (1) (AIDS, 06/2020)
      OBJECTIVE: To examine the clinical burden and disease spectrum, as well as time trends for human T-cell leukemia virus type 1 (HTLV-1) and HTLV type 2 (HTLV-2) hospital admissions. DESIGN: Retrospective, observational study ...
    • Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades 

      Ramos-Rincón, José-Manuel; Menchi-Elanzi, Maroune; Pinargote-Celorio, Héctor; Mayoral, Asunción; González-Alcaide, Gregorio; de Mendoza, Carmen; Barreiro, Pablo; Gómez-Gallego, Felix (1); Corral, Octavio Jorge (1); Soriano, Vicente (1) (AIDS, 02/2022)
      Background: The prognosis of HIV infection dramatically improved after the introduction of triple antiretroviral therapy 25 years ago. Herein, we report the impact of further improvements in HIV management since then, ...
    • Advances in hepatitis B therapeutics 

      Soriano, Vicente (1); Barreiro, Pablo; Cachay, Edward R.; Kottilil, Shyamasundaran; Fernandez-Montero, José V.; Mendoza, Carmen de (Therapeutic Advances in Infectious Disease, 10/2020)
      Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...

    Mi cuenta

    AccederRegistrar

    ¿necesitas ayuda?

    Manual de UsuarioAutorización TFG-M

    Listar

    todo Re-UnirComunidades y coleccionesPor fecha de publicaciónAutoresTítulosPalabras claveTipo documentoTipo de accesoEsta colecciónPor fecha de publicaciónAutoresTítulosPalabras claveTipo documentoTipo de acceso






    Aviso Legal Política de Privacidad Política de Cookies Cláusulas legales RGPD
    © UNIR - Universidad Internacional de La Rioja
     
    Aviso Legal Política de Privacidad Política de Cookies Cláusulas legales RGPD
    © UNIR - Universidad Internacional de La Rioja